237 related articles for article (PubMed ID: 35316110)
1. Managing patients with myelofibrosis and thrombocytopenia.
Yilmaz M; Verstovsek S
Expert Rev Hematol; 2022 Mar; 15(3):233-241. PubMed ID: 35316110
[TBL] [Abstract][Full Text] [Related]
2. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
Tremblay D; Mascarenhas J
Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
[TBL] [Abstract][Full Text] [Related]
3. Cytopenic myelofibrosis: prevalence, relevance, and treatment.
Vachhani P; Verstovsek S; Bose P
Expert Opin Pharmacother; 2023 Jun; 24(8):901-912. PubMed ID: 37070147
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Verstovsek S; Mesa R; Talpaz M; Kiladjian JJ; Harrison CN; Oh ST; Vannucchi AM; Rampal R; Scott BL; Buckley SA; Craig AR; Roman-Torres K; Mascarenhas JO
Haematologica; 2022 Jul; 107(7):1599-1607. PubMed ID: 34551507
[TBL] [Abstract][Full Text] [Related]
5. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
6. Alleviating anemia and thrombocytopenia in myelofibrosis patients.
Cervantes F; Correa JG; Hernandez-Boluda JC
Expert Rev Hematol; 2016 May; 9(5):489-96. PubMed ID: 26891375
[TBL] [Abstract][Full Text] [Related]
7. Novel strategies for challenging scenarios encountered in managing myelofibrosis.
Bose P; Mesa RA
Leuk Lymphoma; 2022 Apr; 63(4):774-788. PubMed ID: 34775887
[TBL] [Abstract][Full Text] [Related]
8. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia.
Mascarenhas J
Expert Rev Hematol; 2022 Aug; 15(8):671-684. PubMed ID: 35983661
[TBL] [Abstract][Full Text] [Related]
9. New approaches to tackle cytopenic myelofibrosis.
Reynolds SB; Pettit K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
[TBL] [Abstract][Full Text] [Related]
10. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
Saeed I; McLornan D; Harrison CN
Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
13. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
Patel AA; Odenike O
Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic advances for splenomegaly in myelofibrosis.
Tremblay D; Mascarenhas J
Expert Opin Pharmacother; 2023 Apr; 24(5):577-585. PubMed ID: 36922391
[TBL] [Abstract][Full Text] [Related]
15. Recent progress of JAK inhibitors for hematological disorders.
Kirito K
Immunol Med; 2023 Sep; 46(3):131-142. PubMed ID: 36305377
[TBL] [Abstract][Full Text] [Related]
16. Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis.
England JT; Gupta V
Expert Opin Pharmacother; 2022 Oct; 23(15):1677-1686. PubMed ID: 36252265
[TBL] [Abstract][Full Text] [Related]
17. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA; Vannucchi AM; Mead A; Egyed M; Szoke A; Suvorov A; Jakucs J; Perkins A; Prasad R; Mayer J; Demeter J; Ganly P; Singer JW; Zhou H; Dean JP; Te Boekhorst PA; Nangalia J; Kiladjian JJ; Harrison CN
Lancet Haematol; 2017 May; 4(5):e225-e236. PubMed ID: 28336242
[TBL] [Abstract][Full Text] [Related]
18. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
19. Pacritinib for myelofibrosis in adults with thrombocytopenia.
Yang DH; Lu Q; Zhu Z; Huang G; Young K
Drugs Today (Barc); 2022 Dec; 58(12):577-589. PubMed ID: 36651066
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Zhang J; Sy O; Mesa RA
Br J Haematol; 2022 Jul; 198(2):317-327. PubMed ID: 35476316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
